文献速递核素与放射性配体治疗

161Tb相比177Lu通过发射内转换电子而非俄歇电子增加细胞核吸收剂量,且[161Tb]Tb-DOTA-LM3的剂量反应高于[161Tb]Tb-DOTATATE

The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE.
PubMed 文献 · J Nucl Med · 2024-10-01

临床前研究显示靶向生长抑素受体的161Tb标记肽在肽受体放射性核素治疗中比177Lu标记类似物更有效。本研究通过细胞剂量学量化细胞核吸收剂量并比较剂量反应曲线,发现161Tb主要因发射内转换电子而非俄歇电子使细胞核吸收剂量增至177Lu类似物的3.6–3.8倍;[161Tb]Tb-DOTA-LM3呈线性-二次剂量反应,而[161Tb]Tb-DOTATATE仅呈线性反应。

要点

  • [161Tb]Tb-DOTATATE和[161Tb]Tb-DOTA-LM3的细胞核吸收剂量分别是对应177Lu标记物的3.6倍和3.8倍。
  • 剂量增加主要源于161Tb发射的内转换电子而非俄歇电子。
  • [161Tb]Tb-DOTA-LM3呈线性-二次剂量反应,[161Tb]Tb-DOTATATE在观察剂量范围内仅呈线性反应。

核心结论

  • 161Tb发射的内转换电子而非俄歇电子导致[161Tb]Tb-DOTATATE和[161Tb]Tb-DOTA-LM3的细胞核吸收剂量高于177Lu标记类似物且克隆存活更低。
  • [161Tb]Tb-DOTATATE的剂量反应不高于[177Lu]Lu-DOTATATE,而[161Tb]Tb-DOTA-LM3观察到额外的二次反应。
  • 由于这种可能由细胞膜损伤引起的二次反应,[161Tb]Tb-DOTA-LM3是比[161Tb]Tb-DOTATATE更有效的161Tb标记放射性肽。

研究设计与样本

  • 临床前体外研究,使用CA20948细胞通过克隆形成实验评估细胞存活。
  • 分别用[161Tb]Tb-和[177Lu]Lu-DOTATATE(激动剂)及[161Tb]Tb-和[177Lu]Lu-DOTA-LM3(拮抗剂)处理细胞。
  • 进行长达7天的细胞结合、内化和解离实验以获得时间积分活度系数。
  • 通过蒙特卡洛模拟计算每种粒子发射类型(俄歇/内转换电子和β-粒子)的S值,考虑球形细胞模型。
  • 计算细胞核吸收剂量后拟合线性或线性-二次模型并评估相对生物效应。

主要发现

  • 放射性肽摄取与放射性核素无关。
  • 饱和受体结合时,[161Tb]Tb-DOTATATE和[161Tb]Tb-DOTA-LM3的细胞核吸收剂量分别是对应177Lu标记物的3.6倍和3.8倍。
  • 细胞核吸收剂量增加主要归因于161Tb额外发射的内转换电子而非俄歇电子。
  • 考虑活度浓度时,[161Tb]Tb-DOTATATE和[161Tb]Tb-DOTA-LM3的存活分数均低于177Lu标记物。
  • 考虑细胞核吸收剂量时,[161Tb]Tb-DOTATATE与[177Lu]Lu-DOTATATE的剂量反应曲线无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preclinical data have shown that 161Tb-labeled peptides targeting the somatostatin receptor are therapeutically more effective for peptide receptor radionuclide therapy than are their 177Lu-labeled counterparts. To further substantiate this enhanced therapeutic effect, we performed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness in vitro. Methods: CA20948 cell survival was assessed after treatment with [161Tb]Tb- and [177Lu]Lu-DOTATATE (agonist) and with [161Tb]Tb- and [177Lu]Lu-DOTA-LM3 (antagonist) via a clonogenic assay. Cell binding, internalization, and dissociation assays were performed up to 7 d to acquire time-integrated activity coefficients. Separate S values for each type of particle emission (Auger/internal conversion [IC] electrons and β- particles) were computed via Monte Carlo simulations, while considering spheric cells. Once the absorbed dose to the cell nucleus was calculated, survival curves were fitted to the appropriate linear or linear-quadratic model and corresponding relative biological effectiveness was evaluated. Results: Although the radiopeptide uptake was independent of the radionuclide, [161Tb]Tb-DOTATATE and [161Tb]Tb-DOTA-LM3 delivered a 3.6 and 3.8 times higher dose to the nucleus, respectively, than their 177Lu-labeled counterparts on saturated receptor binding. This increased nucleus-absorbed dose was mainly due to the additional emission of IC and not Auger electrons by 161Tb. When activity concentrations were considered, both [161Tb]Tb-DOTATATE and [161Tb]Tb-DOTA-LM3 showed a lower survival fraction than did labeling with 177Lu. When the absorbed dose to the nucleus was considered, no significant difference could be observed between the dose-response curves for [161Tb]Tb- and [177Lu]Lu-DOTATATE. [161Tb]Tb-DOTA-LM3 showed a linear-quadratic dose response, whereas [161Tb]Tb-DOTATATE showed only a linear dose response within the observed dose range, suggesting additional cell membrane damage by Auger electrons. Conclusion: The IC, rather than Auger, electrons emitted by 161Tb resulted in a higher absorbed dose to the cell nucleus and lower clonogenic survival for [161Tb]Tb-DOTATATE and [161Tb]Tb-DOTA-LM3 than for the 177Lu-labeled analogs. In contrast, [161Tb]Tb-DOTATATE showed no higher dose response than [177Lu]Lu-DOTATATE, whereas for [161Tb]Tb-DOTA-LM3 an additional quadratic response was observed. Because of this quadratic response, potentially caused by cell membrane damage, [161Tb]Tb-DOTA-LM3 is a more effective radiopeptide than [161Tb]Tb-DOTATATE for labeling with 161Tb.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Spoormans K, Struelens L, Vermeulen K, et al. The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE. J Nucl Med. 2024. PMID: 39209546. doi:10.2967/jnumed.124.267873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。